The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Type 1 Receptor Antagonist Therapy Is Associated with Prolonged Patient and Graft Survival after Renal Transplantation
Abstract
Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type 1 receptor blockers (ARB) reduce cardiovascular death in the general population, but data for renal transplant recipients remain elusive. Similarly, ACEI/ARB have been shown to reduce proteinuria, but data on graft survival are lacking. Therefore a retrospective open cohort study was conducted of 2031 patients who received their first renal allograft at the Medical University of Vienna between 1990 and 2003 and survived at least 3 mo. Patient and graft survival was compared between patients with versus without ACEI and/or ARB therapy. Data were analyzed with and without propensity score models for ACEI/ARB therapy. Medication and comorbidities were analyzed as time-dependent variables in the Cox regression analyses. Ten-year survival rates were 74% in the ACEI/ARB group but only 53% in the noACEI/ARB group (P<0.001). The hazard ratio (HR) of ACEI/ARB use for mortality was 0.57 (95% confidence interval [CI] 0.40 to 0.81) compared with nonuse. Ten-year actual graft survival rate was 59% in ACEI/ARB patients but only 41% in nonusers (P=0.002). The HR of actual graft failure for ACEI/ARB recipients was 0.55 (95% CI 0.43 to 0.70) compared with nonusers; the HR of functional graft survival was 0.56 (95% CI 0.40 to 0.78). Ten-year unadjusted functional graft survival rates were 76% among ACEI/ARB patients and 71% in noACEI/ARB recipients (P=0.57). In summary, the use of ACEI/ARB therapy was associated with longer patient and graft survival after renal transplantation. More frequent use of these medications may reduce the high incidence of death and renal allograft failure in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
Applied Survival Analysis: Regression Modeling of Time-to-Event Data
Hosmer, D. W., Lemeshow, S. A., & May, S. J. (2008) · Cited by 3,030
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142 · cited 1×
“inhibitor (CNI); (2) triple therapy with corticosteroids, azathioprine,”
Background(2000) · PubMed · Cited by 2,095
Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Solez, K., Axelsen, R. A., Benediktsson, H., Burdick, J. F., Cohen, A. H., Colvin, R. B., Croker, B. P., Droz, D., Dunnill, M. S., Halloran, P. F., et al. (1993) · Kidney International · doi:10.1038/ki.1993.259 · Cited by 1,424
Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients
Kalantar-Zadeh, K., Block, G., Humphreys, M. H., & Kopple, J. D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00803.x · Cited by 1,247
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
Dragun, D., Müller, D. N., Bräsen, J. H., Fritsche, L., Nieminen-Kelhä, M., Dechend, R., Kintscher, U., Rudolph, B., Hoebeke, J., Eckert, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa035717 · Cited by 868
Goodkin, D. A., Bragg-Gresham, J. L., Koenig, K. G., Wolfe, R. A., Akiba, T., Andreucci, V. E., Saito, A., Rayner, H. C., Kurokawa, K., Port, F. K., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100127.54107.57 · Cited by 761
Analysing Survival Data From Clinical Trials and Observational Studies
(1996) · Technometrics · doi:10.1080/00401706.1996.10484530 · Cited by 663
Estimating and Using Propensity Scores with Partially Missing Data
D'Agostino, R. B., & Rubin, D. B. (2000) · Journal of the American Statistical Association · doi:10.1080/01621459.2000.10474263 · Cited by 300
Wolf, G., & Ritz, E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00145.x · Cited by 289
Mariat, C., Alamartine, É., Barthélemy, J., de Filippis, J. P., Thibaudin, D., Berthoux, P., Laurent, B., Thibaudin, L., & Berthoux, F. C. (2003) · Kidney International · doi:10.1111/j.1523-1755.2004.00350.x · Cited by 126
Review: Arterial stiffness and the renin-angiotensin-aldosterone system
Mahmud, A., & Feely, J. (2004) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2004.025 · Cited by 117
Zhuo, J. L., Mendelsohn, F. A. O., & Ohishi, M. (2002) · Hypertension · doi:10.1161/hy0202.103417 · Cited by 98
ACE Inhibitor Versus β-Blocker for the Treatment of Hypertension in Renal Allograft Recipients
Hausberg, M., Barenbrock, M., Hohage, H., Müller, S., Heidenreich, S., & Rahn, K. H. (1999) · Hypertension · doi:10.1161/01.hyp.33.3.862 · Cited by 94
Hypertension, antihypertensive agents and outcomes following renal transplantation
Tutone, V. K., Mark, P. B., Stewart, G. A., Tan, C., Rodger, R., Geddes, C., & Jardine, A. G. (2005) · Clinical Transplantation · doi:10.1111/j.1399-0012.2004.00315.x · Cited by 81
Renoprotective Effects of Losartan in Renal Transplant Recipients
Inigo, P. J., Campistol, J. M., Saracho, R., et al. (2003) · Nephron Clinical Practice · doi:10.1159/000074321 · Cited by 34
Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy
Haas, M., Leko-Mohr, Z., Erler, C., & Mayer, G. J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.34883 · Cited by 24
Cited by
Management of Hypertension in Chronic Kidney Disease
Pugh, D., Gallacher, P. J., & Dhaun, N. (2019) · Drugs · doi:10.1007/s40265-019-1064-1 · Cited by 401
Diagnosis and prevention of chronic kidney allograft loss
Nankivell, B. J., & Kuypers, D. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60699-5 · Cited by 324
Prevention of cardiovascular disease in adult recipients of kidney transplants
Jardine, A. G., Gaston, R. S., Fellstrom, B. C., & Holdaas, H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61334-2 · Cited by 281
Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review
Laghlam, D., Jozwiak, M., & Nguyen, L. S. (2021) · Cells · doi:10.3390/cells10071767 · Cited by 96
Metadata
- Authors
- Heinze, G., Mitterbauer, C., Regele, H., Kramar, R., Winkelmayer, W. C., Curhan, G. C., & Oberbauer, R.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-03
- Volume
- 17
- Issue
- 3
- Pages
- 889-899
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2115154092
- Cited by
- 276
- References
- 31
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.